114 related articles for article (PubMed ID: 31800508)
1. Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for evaluating the clinicopathological grade in patients with non-Hodgkin's lymphoma: a prospective study.
Shinya T; Otomi Y; Dimitrakopoulou-Strauss A; Kubo M; Kondo M; Otomo M; Terazawa K; Bando Y; Harada M
Nucl Med Commun; 2020 Jan; 41(1):26-33. PubMed ID: 31800508
[TBL] [Abstract][Full Text] [Related]
2. Preliminary clinical assessment of dynamic
Shinya T; Otomi Y; Kubo M; Kinoshita M; Takechi K; Uyama N; Yamanaka M; Terazawa K; Toba H; Bando Y; Otsuka H; Harada M
Ann Nucl Med; 2019 Jun; 33(6):414-423. PubMed ID: 30911883
[TBL] [Abstract][Full Text] [Related]
3. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
4. Correlations between maximum standardized uptake value measured via
Li H; Wang X; Zhang L; Yi X; Qiao Y; Jin Q
J Cancer Res Ther; 2019; 15(7):1581-1588. PubMed ID: 31939441
[TBL] [Abstract][Full Text] [Related]
5. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma.
Li XF; Fu Q; Dong YW; Liu JJ; Song XY; Dai D; Zuo C; Xu WG
World J Gastroenterol; 2016 Sep; 22(34):7787-96. PubMed ID: 27678362
[TBL] [Abstract][Full Text] [Related]
6. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
Schöder H; Noy A; Gönen M; Weng L; Green D; Erdi YE; Larson SM; Yeung HW
J Clin Oncol; 2005 Jul; 23(21):4643-51. PubMed ID: 15837966
[TBL] [Abstract][Full Text] [Related]
7. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of dynamic 18F-fluorodeoxyglucose positron-emission tomography / computed tomography in the differential diagnoses of musculoskeletal lesions.
Shinya T; Otomi Y; Nishisho T; Beuthien-Baumann B; Irahara S; Kubo M; Otsuka H; Bando Y; Sairyo K; Harada M
J Med Invest; 2021; 68(1.2):96-104. PubMed ID: 33994487
[TBL] [Abstract][Full Text] [Related]
9. Preliminary clinical assessment of dynamic carbon-11 methionine positron-emission tomography/computed tomography for the diagnosis of the pathologies in patients with musculoskeletal lesions: a prospective study.
Shinya T; Otomi Y; Nishisho T; Beuthien-Baumann B; Kubo M; Otsuka H; Bando Y; Yanagawa H; Sairyo K; Harada M
Eur J Hybrid Imaging; 2020 Aug; 4(1):15. PubMed ID: 34191157
[TBL] [Abstract][Full Text] [Related]
10. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
[TBL] [Abstract][Full Text] [Related]
11. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
Zhang Q; Tian T; Wang L; Qiu H; Li D
Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
[TBL] [Abstract][Full Text] [Related]
13. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
14. Value of contrast-enhanced ultrasound and PET/CT in assessment of extramedullary lymphoma.
Jiang W; Xue H; Wang Q; Zhang X; Wang Z; Zhao C
Eur J Radiol; 2018 Feb; 99():88-93. PubMed ID: 29362156
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Hanaoka K; Hosono M; Usami K; Tatsumi Y; Yamazoe Y; Komeya Y; Tsuchiya N; Ishii K; Sumita M
Nucl Med Commun; 2011 Aug; 32(8):678-83. PubMed ID: 21499162
[TBL] [Abstract][Full Text] [Related]
16.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
17. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.
Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC
Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
[TBL] [Abstract][Full Text] [Related]
19. Does dual-time-point
Wu B; Zhao Y; Zhang Y; Tan H; Shi H
Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
[TBL] [Abstract][Full Text] [Related]
20. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
